Findings

What do systematic reviews say?

8 questions · 8 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 8 · 100%

IBDQ at week 6 · people with active UC

1 finding from 1 review

ACR 50% improvement · patients with rheumatoid arthritis

Golimumab 50 mg every 4 weeks + MTX leads to higher ACR50 compared with placebo + MTX (high certainty).

1 finding from 1 review

Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 2.57 [1.34, 4.94]
4 studies · 919 participants
High

DAS (low or remission) · patients with rheumatoid arthritis

Golimumab 50 mg every 4 weeks + MTX leads to higher disease activity (DAS Remission) compared with placebo + MTX (high certainty).

1 finding from 1 review

Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 5.12 [1.67, 15.66]
4 studies · 919 participants
High

Physical function · patients with rheumatoid arthritis

1 finding from 1 review

Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
1 study · 308 participants
High

Adverse events · patients with rheumatoid arthritis

Golimumab 50 mg every 4 weeks + MTX showed no clear difference in adverse Events compared with placebo + MTX (high certainty).

1 finding from 1 review

Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 1.05 [0.93, 1.18]
4 studies · 918 participants
High

Serious adverse events · patients with rheumatoid arthritis

Golimumab 50 mg every 4 weeks + MTX showed no clear difference in serious Adverse Events compared with placebo + MTX (high certainty).

1 finding from 1 review

Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 1.05 [0.62, 1.78]
4 studies · 918 participants
High

Study Withdrawals · patients with rheumatoid arthritis

Golimumab 50 mg every 4 weeks + MTX leads to lower all Withdrawals compared with placebo + MTX (high certainty).

1 finding from 1 review

Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 0.5 [0.31, 0.81]
4 studies · 917 participants
High

Withdrawals due to adverse events · patients with rheumatoid arthritis

Golimumab 50 mg every 4 weeks + MTX showed no clear difference in withdrawals due to Adverse Events compared with placebo + MTX (high certainty).

1 finding from 1 review

Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 0.56 [0.24, 1.29]
3 studies · 599 participants
High